PCM
TEVA icon

Prelude Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Prelude Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$1K – 2334
2020
Q2 		$1K Sell
100
-2,900
-97% -$32.8K ﹤0.01% 1889
2020
Q1 		$27K Buy
3,000
+2,600
+650% +$26.6K ﹤0.01% 911
2019
Q4 		$4K Buy
+400
New +$3.57K ﹤0.01% 1792
2019
Q2 		– Sell
-200
Closed -$3K – 2135
2019
Q1 		$3K Buy
+200
New +$3.53K ﹤0.01% 1672
2018
Q4 		– Sell
-60,000
Closed -$1.29M – 2147
2018
Q3 		$1.29M Buy
+60,000
New +$1.39M 0.08% 299

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's TEVA Position: Q1 2026 in Review

Prelude Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 53% in Q1 2026, buying an estimated $1.72M and bringing the position to 154,970 shares worth $4.67M. The position accounts for 0.36% of the portfolio, ranked #57.

Prelude Capital Management first reported a position in TEVA in Q2 2014 and has held it in 26 quarters since. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Prelude Capital Management held 154,970 shares of Teva Pharmaceuticals worth $4.67M as of Q1 2026.
  • Prelude Capital Management bought 53,500 Teva Pharmaceuticals shares in Q1 2026, an estimated $1.72M.
  • Teva Pharmaceuticals made up 0.36% of Prelude Capital Management's portfolio in Q1 2026, its #57 holding.
  • Prelude Capital Management first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.